Evidence map›Paper›PMID 37816665›Full record

ArticleAddiction (Abingdon, England)2024

Drug overdose risk with benzodiazepine treatment in young adults: Comparative analysis in privately and publicly insured individuals.

Greta A Bushnell, Moira A Rynn, Tobias Gerhard, Katherine M Keyes, Deborah S Hasin, Magdalena Cerdá, Abner Nyandege, Mark Olfson

Open access · hybridAbstract read
In one paragraph

Article in Addiction (Abingdon, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Greta A BushnellCenter for Pharmacoepidemiology and Treatment Sciences, Rutgers Institute for Health, Health Care Policy and Aging Research, New Brunswick, NJ, USA.ORCID 0000-0002-4056-8405
Moira A RynnDepartment of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC, USA.
Tobias GerhardCenter for Pharmacoepidemiology and Treatment Sciences, Rutgers Institute for Health, Health Care Policy and Aging Research, New Brunswick, NJ, USA.
Katherine M KeyesDepartment of Epidemiology, Columbia University Mailman School of Public Health, New York, NY, USA.
Deborah S HasinDepartment of Epidemiology, Columbia University Mailman School of Public Health, New York, NY, USA.ORCID 0000-0002-6533-7021
Magdalena CerdáCenter for Opioid Epidemiology and Policy, Department of Population Health, New York University School of Medicine, New York, NY, USA.ORCID 0000-0001-8441-7046
Abner NyandegeCenter for Pharmacoepidemiology and Treatment Sciences, Rutgers Institute for Health, Health Care Policy and Aging Research, New Brunswick, NJ, USA.
Mark OlfsonDepartment of Epidemiology, Columbia University Mailman School of Public Health, New York, NY, USA.
Rutgers, The State University of New Jersey · USColumbia University Irving Medical Center · USColumbia University · USDuke University · USNew York University · US

Funding

Benzodiazepine-related harms in young people: Informing policy, interventions, and prescribingK01DA050769 · NIDA · RUTGERS BIOMEDICAL/HEALTH SCIENCES-RBHS · PI BUSHNELL, GRETA · 2021 to 2025
$1.0M
NIDA NIH HHS 5K01DA050769NIDA NIH HHS K01 DA050769
6 · The paper itself

Abstract

BACKGROUND AND

aimsBenzodiazepines (BZDs) carry a risk for drug overdose and are prescribed alone or simultaneously with selective-serotonin reuptake inhibitors (SSRIs) for the treatment of anxiety and depression in young adults. We aimed to measure risks of drug overdose following BZD treatment initiation, and simultaneous BZD and SSRI initiation, compared with SSRI treatment alone in young adults with depression or anxiety. DESIGN, SETTING,

participantsThe cohort study used administrative databases covering privately (MarketScan, 1/1/2009-12/31/2018) and publicly (Medicaid, 1/1/2015-12/31/2016) insured young adults (18-29 years) in the United States. Those with depression or anxiety diagnoses newly initiating BZD or SSRI treatment (without BZD or SSRI prescriptions in prior year) were included. Simultaneous "BZD + SSRI" initiation was defined as starting BZD and SSRI treatment on the same day. The cohorts included 604 664 privately insured young adults (BZD = 22%, BZD + SSRI = 10%, SSRI = 68%) and 110 493 publicly insured young adults (BZD = 23%, BZD + SSRI = 5%, SSRI = 72%). MEASUREMENTS: Incident medically treated drug overdose events were identified from emergency department and inpatient encounters (ICD poisoning codes) within 6 months of treatment initiation. Crude and propensity-score adjusted cumulative incidence and hazard ratios (HR) were estimated. Sub-analyses evaluated drug overdose intent.

findingsAdjusted HRs of drug overdose for BZD vs. SSRI treatment was 1.36 (95% confidence interval [CI]:1.23-1.51) in privately and 1.59 (95%CI:1.37-1.83) in publicly insured young adults. The adjusted HRs of drug overdose for BZD + SSRI treatment vs. SSRI treatment were 1.99 (95%CI:1.77-2.25) in privately and 1.98 (95%CI:1.47-2.68) in publicly insured young adults.

conclusionsAmong young adults in the United States, initiating benzodiazepine treatment for anxiety and depression, alone or simultaneously with selective-serotonin reuptake inhibitors (SSRI), appears to have an increased risk of medically treated drug overdose compared with SSRI treatment alone. These associations were observed in publicly and privately insured individuals.

Indexed as

BenzodiazepinesDrug OverdoseCohort StudiesHumansMedicaidRetrospective StudiesSelective Serotonin Reuptake InhibitorsUnited StatesYoung AdultBenzodiazepinesSelective Serotonin Reuptake Inhibitorsanxiety disorderbenzodiazepinecohortdepressionoverdosepharmacoepidemiologypoisoningselective serotonin reuptake inhibitoryoung adult

Identifiers

PMID37816665
PMCPMC10838605
OpenAlexW4387516133

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.